Treatment with cyclosporin in patients with psoriatic arthritis: results of clinical assessment.

Abstract

An open 18-week study with a preparation of cyclosporin administered to patients with psoriatic arthritis confirmed the therapeutic efficacy of the preparation. Given the low frequency of adverse effects (at the initial and maintenance daily dose), the preparation could also be considered relatively safe. A pronounced improvement in psoriatic symptoms was observed during the study. As early as 2 weeks after administration of an average daily dose of cyclosporin A of 4.8 mg/kg, skin symptoms improved by 65.5%. The most intense effect on the activity of arthritis was observed after 18 weeks. The lowest optimal effective maintenance dose was 3.26 mg/kg/day. Improvement was achieved after an average of 10 weeks' cyclosporin administration.

• Authors: H Raffayová, J Rovenský, F Mális
• Journal: International journal of clinical pharmacology research (Int J Clin Pharmacol Res) Vol. 20 Issue 1-2 Pg. 1-11 ( 2000) ISSN: 0251-1649 [Print] Switzerland
• PMID: 11146896 (Publication Type: Case Reports, Clinical Trial, Journal Article, Review)

Chemical References

• Dermatologic Agents
• Cyclosporine
• Urea
• Cholesterol
• Creatinine

Topics

• Adult
• Arthritis, Psoriatic (drug therapy, physiopathology)
• Cholesterol (blood)
• Creatinine (blood)
• Cyclosporine (therapeutic use)
• Dermatologic Agents (therapeutic use)
• Drug Monitoring
• Humans
• Male
• Middle Aged
• Urea (blood)